<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Office spirometry</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Office spirometry</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Office spirometry</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Kaminsky, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Meredith C McCormack, MD, MHS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Spirometry is used to measure forced expiratory flow rates and volumes. It is the most commonly used pulmonary function test and is useful in the evaluation of patients with respiratory symptoms (eg, dyspnea, cough, wheeze), and the monitoring of lung function in patients with lung disease, being treated with drugs that can affect lung function, or at risk of lung disease (eg, smoking, occupational exposures, family history).</p><p>In the office setting, spirometry is typically used to detect, confirm, and monitor obstructive airway diseases (eg, asthma, chronic obstructive pulmonary disease [COPD]) and monitor known restrictive lung disease [<a href="#rid1">1-5</a>]. In this setting, the clinician must be knowledgeable about issues related to equipment, performance of the forced expiratory maneuver, and interpretation of the data to obtain reliable and clinically useful information [<a href="#rid6">6-8</a>]. International guidelines for performance of office spirometry have been published [<a href="#rid9">9,10</a>]. Spirometry is not recommended as a screening test for asymptomatic adults [<a href="#rid4">4,11</a>], but rather facilitates diagnosis of respiratory diseases.</p><p>The performance of spirometry in the office setting will be reviewed here. More general issues related to pulmonary function tests, the interpretation of flow volume loops, and the technique of bronchoprovocation testing are discussed separately. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a> and  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops"</a> and  <a class="medical medical_review" href="/d/html/525.html" rel="external">"Bronchoprovocation testing"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EQUIPMENT AND HYGIENE</span><span class="headingEndMark"> — </span>Office spirometers should meet equipment specifications as described in international guidelines [<a href="#rid5">5,10,12,13</a>]. The majority of spirometers manufactured since 1990 are accurate, although some flow-sensing office spirometers can produce falsely high results [<a href="#rid14">14-16</a>]. Reference standards are discussed separately. (See  <a class="medical medical_review" href="/d/html/6971.html" rel="external">"Selecting reference values for pulmonary function tests"</a>.)</p><p>To avoid cross-contamination between patients when using permanent flow sensors, it is preferable to employ single-use disposable flow sensors and disposable in-line bacterial and viral filters. Together, these measures dramatically reduce the risk of inhalational cross contamination. Disposable one-way mouthpieces may also be used.</p><p>Volume sensing spirometers maintain accuracy over many years but are more difficult to clean and are rarely used for office spirometry.</p><p>Spirometry and other pulmonary function test (PFT) maneuvers can promote coughing and aerosol generation. During times of high respiratory virus community prevalence, allowing time between patients for air exchange is prudent for prevention of patient-to-patient transmission. Transmission risk can also be diminished by using adequately ventilated spaces (eg, rooms with at least six air exchanges per hour). Use of face masks by laboratory staff should be encouraged.</p><p class="headingAnchor" id="H3"><span class="h1">QUALITY CONTROL</span><span class="headingEndMark"> — </span>Office spirometers should accurately measure the forced expiratory volume in one second (FEV<sub>1</sub>), forced expiratory volume in six seconds (FEV<sub>6</sub>), and forced vital capacity (FVC) and also provide quality checks and error messages. A survey of 17 spirometers used in primary care offices found only 1 of 17 met accuracy criteria; clearly manufacturers and practitioners need to be aware of potentially significant quality issues related to office spirometry [<a href="#rid17">17</a>].</p><p>In addition to internal calibration performed by the device, daily calibration checks with a three liter syringe are recommended [<a href="#rid10">10</a>]. When performing a calibration check, the three-liter syringe should be discharged into the spirometer three times. The volumes read by the machine should be within 3 percent of three liters. If the spirometer reading remains outside these limits after replacing the flow sensor, the device should be removed from use until checked by the manufacturer.</p><p>It is also essential that the nurse or technician enter correct values for age, height, and sex at birth, as these values are used to generate the appropriate predicted values for the individual patient. Height should be measured with shoes off, preferably using a stadiometer, rather than relying on the patient's stated height. Percent predicted values that are unexpectedly higher or lower than expected are a clue that an incorrect age or height value may have been entered. Waist circumference, while not used to calculate predicted normal values, can also be measured because abdominal obesity is a common cause of mildly low values for FEV<sub>1</sub> and FVC [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H4"><span class="h1">PROCEDURE</span><span class="headingEndMark"> — </span>Patients are usually seated during spirometry, unless otherwise noted. Nose clips or manual occlusion of the nares help to prevent air leakage through the nasal passages, although spirometry can be performed without nasal occlusion [<a href="#rid19">19</a>]. The deep inhalation should occur before the mouthpiece is placed in the mouth. Immediately after the deep inhalation, the mouthpiece is placed just inside the mouth between the teeth. The lips should be sealed tightly around the mouthpiece to prevent air leakage during maximal forced exhalation. The patient should then be instructed to blast out the air without hesitation (within two seconds of reaching full inflation). Exhalation should last until a plateau in exhaled volume is reached, or a maximum of 15 seconds. However, if measuring FEV<sub>6</sub> as a surrogate for FVC, then exhalation need only last at least six seconds. To fully evaluate flow volume loops, it is necessary to perform a complete inspiratory maneuver at the end of the test. The maximal inspiration at the end of test requires vigorous coaching to achieve good quality results and patients should be informed that this aspect of the maneuver feels somewhat uncomfortable. (See  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops"</a>.)</p><p>The patient is allowed to rest for several seconds and the procedure is repeated. Usually, three maneuvers are performed, although additional tests may be needed if one or more of the curves are unacceptable.</p><p class="headingAnchor" id="H5"><span class="h1">COACHING THE PATIENT</span><span class="headingEndMark"> — </span>The most important task of the technician or person performing the test is to obtain maximal, reproducible efforts from the patient.</p><p>Even with the use of accurate instruments, office spirometry results may be misleading if the patient's efforts are submaximal. Unlike most other medical tests in which the patient remains passive, accurate spirometry results require significant exertion on the part of the patient.</p><p>The technician must instruct and encourage the patient to perform the breathing maneuvers in three phases  (<a class="graphic graphic_figure graphicRef55460" href="/d/graphic/55460.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Phase 1: Coach the patient to take as deep a breath as possible</p><p class="bulletIndent1"><span class="glyph">●</span>Phase 2: Strongly prompt the patient to blast out the air into the spirometer without hesitation after reaching a full inspiration</p><p class="bulletIndent1"><span class="glyph">●</span>Phase 3: Encourage the patient to continue exhaling until a plateau in exhaled volume or 15 seconds is reached, unless just measuring FEV<sub>6</sub> in which case the exhalation should last at least six seconds (three seconds for children)</p><p></p><p>Patients in whom a flow volume loop is needed will need to perform an additional phase of deep and forceful inspiration to total lung capacity immediately after phase 3.</p><p class="headingAnchor" id="H6"><span class="h1">ADEQUACY OF TEST</span><span class="headingEndMark"> — </span>An adequate test usually requires three acceptable and repeatable forced vital capacity (FVC) maneuvers [<a href="#rid10">10</a>]. The clinician and technician must learn to recognize the patterns of acceptable and unacceptable efforts, since poorly performed maneuvers often mimic disease patterns. Detection of poorly performed maneuvers requires direct inspection of both flow-volume curves and volume-time spirograms  (<a class="graphic graphic_figure graphicRef57832" href="/d/graphic/57832.html" rel="external">figure 2</a>) [<a href="#rid12">12,20</a>].</p><p>An acceptable maneuver requires a sharp peak in the flow curve and an expiratory duration that reaches a plateau of exhaled volume or 15 seconds, or greater than six seconds if measuring FEV<sub>6</sub> instead of FVC  (<a class="graphic graphic_figure graphicRef65057" href="/d/graphic/65057.html" rel="external">figure 3</a>). At least three acceptable maneuvers should be available for analysis.</p><p>Repeatability is determined by comparing the FVC and FEV<sub>1</sub> values of the maneuvers. The two highest values for FVC and for FEV<sub>1</sub> should be within 0.15 L of each other (for adults; the limit is 0.10 L for children) [<a href="#rid10">10,21</a>]. </p><p>The grading system for the quality of spirometry factors in the number of acceptable maneuvers and the degree of repeatability for FEV<sub>1</sub> and FVC separately  (<a class="graphic graphic_table graphicRef129852" href="/d/graphic/129852.html" rel="external">table 1</a>) [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H7"><span class="h1">INTERPRETATION</span><span class="headingEndMark"> — </span>All tracings from the forced expiratory maneuvers should be examined for acceptability and repeatability, according to the criteria mentioned above. The study should then be classified as normal or abnormal, the latter showing an obstructive, a possible restrictive, or a possible mixed pattern. Lung volumes are necessary to confirm whether or not the patient has a restrictive deficit. The severity of the ventilatory impairment is then assessed, according to the algorithm  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 1</a>). (See <a class="local">'Forced expiratory volume in one second'</a> below and  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Forced vital capacity</span><span class="headingEndMark"> — </span>The forced vital capacity (FVC) (also known as the forced expiratory volume) is the maximal volume of air exhaled with a maximally forced effort from a position of full inspiration and is expressed in liters [<a href="#rid10">10</a>]. The highest FVC from the three acceptable forced expiratory maneuvers is used for interpretation [<a href="#rid10">10</a>].</p><p>The FVC may be reduced by suboptimal patient effort, airflow limitation, restriction (eg, from lung parenchymal, pleural, or thoracic cage disease), or a combination of these  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 1</a>). In general, a low FVC needs further evaluation with full pulmonary function tests to determine whether lung restriction is present [<a href="#rid22">22</a>]. Patients with obstruction and low FVC frequently demonstrate air trapping or failure to complete a full exhalation rather than an additional restrictive process. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p>When FVC is low, restriction is not confirmed by lung volumes, and there is not obstruction (based on FEV<sub>1</sub>/FVC), this represents a "nonspecific" pattern. Nonspecific patterns are not clearly indicative of any lung disease subtype but may be associated with either ongoing or future obstructive or restrictive diseases [<a href="#rid23">23</a>]. Repeat testing to reassess lung function after several months to a year may be useful.</p><p>Due to these potential problems with air trapping and incomplete exhalation, FVC is not used to grade restriction severity. We prefer to assess the severity of restrictive deficits by applying the z-score approach to total lung capacity measurements, when available. If lung volumes are not available, FEV<sub>1</sub> may be used to assess the severity of previously established restriction, as was recommended in prior guidelines [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p>The slow vital capacity (SVC) is the maximal volume of air exhaled after a maximal inspiration, but without a forced effort. The SVC is rarely measured outside of hospital-based pulmonary function labs. For normal subjects, the slow and forced vital capacities are very close, whereas patients with airflow limitation tend to have a lower FVC than SVC. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults", section on 'Spirometry'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Forced expiratory volume in six seconds</span><span class="headingEndMark"> — </span>The forced expiratory volume in six seconds (FEV<sub>6</sub>) is sometimes used as a surrogate for FVC [<a href="#rid19">19,24</a>]. The FEV<sub>6</sub> has the advantage of being more reproducible than the FVC and less physically demanding for the patient.</p><p class="headingAnchor" id="H10"><span class="h2">Forced expiratory volume in one second</span><span class="headingEndMark"> — </span>The forced expiratory volume in one second (FEV<sub>1</sub>) is the maximal volume of air exhaled in the first second of a forced exhalation that follows a full inspiration, expressed in liters [<a href="#rid19">19</a>]. The FEV<sub>1</sub> reflects the average flow rate during the first second of the FVC maneuver. The FEV<sub>1</sub> is the most important spirometric variable for assessment of the severity of airflow obstruction  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 1</a>). The highest FEV<sub>1</sub> from the three acceptable forced expiratory maneuvers is used for interpretation, even if it does not come from the maneuver with the highest FVC [<a href="#rid10">10</a>].</p><p>In patients with asthma, the FEV<sub>1</sub> typically declines with clinical worsening of airways obstruction and increases with successful treatment of airways obstruction. The FEV<sub>1</sub> should be used for determining the degree of obstruction (mild, moderate, or severe) and for serial comparisons when following patients with asthma or chronic obstructive pulmonary disease (COPD).</p><p>FEV<sub>1</sub> may also be used to grade the severity of restrictive or mixed obstructive/restrictive disorders once restriction has been confirmed by lung volumes; however, we prefer to grade pure restriction using total lung capacity when this measurement is available  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 1</a>) [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p>The measured FEV<sub>1</sub> should be reported based on z-score, instead of percent predicted. This measurement strategy helps to avoid age, sex, and height bias and is associated with important clinical outcomes [<a href="#rid25">25,26</a>]. The lower limit of normal (LLN) for FEV<sub>1</sub> and other spirometry measures is defined by z-score &lt;-1.645, which is equivalent to the fifth percentile in the distribution of healthy never-smokers. This replaces using a fixed percent of predicted value, which does not incorporate demographic features [<a href="#rid25">25,27</a>]. An FEV<sub>1 </sub>within the normal range may still represent a mild ventilatory impairment if obstruction or restriction is confirmed using other measures.</p><p>Reference equations from the Global Lung Function Initiative (GLI), which assessed healthy individuals age 3 to 95 years across ethnic and geographic groups in 26 countries, are recommended for both pediatric and adult patients [<a href="#rid25">25,28</a>]. These reference equations are endorsed by multiple international expert groups and replace the older generation of equations, including those derived from the NHANES III study [<a href="#rid21">21,29</a>]. The GLI offers equations that account for race/ethnicity and an alternative "GLI-Global" composite equation that can be applied universally [<a href="#rid30">30</a>]. While accumulating evidence has demonstrated flaws in the use of the race/ethnicity-specific equations, the effects of shifting to universal equations are not yet fully understood. (See  <a class="medical medical_review" href="/d/html/6971.html" rel="external">"Selecting reference values for pulmonary function tests"</a> and  <a class="medical medical_review" href="/d/html/6971.html" rel="external">"Selecting reference values for pulmonary function tests", section on 'Effect of race/ethnicity'</a>.)</p><p>As a rough guideline, the predicted FEV<sub>1</sub> for a 50-year-old of average height is about 4 L for a male and 3 L for a female. When predicted values have not been calculated, patients with severe COPD generally have an FEV<sub>1</sub> less than one liter, while those with moderate COPD have an FEV<sub>1</sub> between 1 and 1.5 liters. Individuals with an FEV<sub>1</sub> ≤75 percent of predicted are more likely to report dyspnea, wheezing, or cough, than those with an FEV<sub>1</sub> &gt;75 percent predicted [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/6971.html" rel="external">"Selecting reference values for pulmonary function tests"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Ratio of FEV1/FVC</span><span class="headingEndMark"> — </span>The FEV<sub>1</sub>/FVC ratio is the fraction of the forced vital capacity that can be exhaled in the first second. It is the most important parameter for detecting airflow obstruction in diseases like asthma and COPD  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 1</a>). However, once it has been determined that a patient has airways obstruction, the FEV<sub>1</sub>/FVC ratio is not useful for gauging severity of disease, since the FVC often decreases with increasing obstruction due to air trapping or premature termination of exhalation. The FEV<sub>1</sub>, not the FEV<sub>1</sub>/FVC ratio, should be used to monitor patients with asthma or COPD. (See  <a class="medical medical_review" href="/d/html/569.html" rel="external">"Pulmonary function testing in asthma"</a> and  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a>.)</p><p>The use of z-score &lt;-1.645 or the fifth percentile LLN for FEV<sub>1</sub>/FVC to detect airway obstruction reduces the misclassification associated with using a fixed threshold of 0.7 [<a href="#rid27">27,32-35</a>].</p><p>If FEV<sub>1</sub>/FVC is low, but FEV<sub>1</sub> is normal, this is still considered indicative of mild airflow obstruction. In some cases, a low FEV<sub>1</sub>/FVC in the presence of a low FEV<sub>1</sub> is classified as reflecting dysanapsis, or airways size being too small relative to lung volume size. While dysanapsis may be a physiologically normal variant, it has also been associated with COPD [<a href="#rid36">36</a>], bronchodilator responsiveness, and [<a href="#rid37">37</a>] severe asthma in children with obesity [<a href="#rid38">38</a>].</p><p>If FEV<sub>1</sub>/FVC is normal, but FEV<sub>1</sub> is low, this may represent restriction, which should be evaluated by lung volumes. When lung volumes are not available, this pattern has also been labeled "Preserved Ratio Impaired Spirometry", or PRISm. It is unclear if PRISm is a distinct phenotype of lung disease, but multiple studies have demonstrated that PRISm is associated with increased cardiopulmonary disease and mortality [<a href="#rid39">39-41</a>].</p><p>When FVC maneuvers are routinely stopped after six seconds, the FEV<sub>1</sub>/FEV<sub>6</sub> may replace the FEV<sub>1</sub>/FVC [<a href="#rid42">42</a>]. The advantages of the FEV<sub>1</sub>/FEV<sub>6</sub> include less frustration for the patient and technician trying to achieve an end-of-test plateau, less chance of syncope, shorter testing time, and better repeatability, without loss of sensitivity or specificity [<a href="#rid24">24,43-45</a>]. The appropriate lower limit of normal for FEV<sub>1</sub>/FEV<sub>6</sub> from NHANES III should be used [<a href="#rid29">29,46</a>]; unfortunately, the GLI equations do not include prediction equations for FEV<sub>6</sub>.</p><p class="headingAnchor" id="H12"><span class="h2">Other flow measures</span><span class="headingEndMark"> — </span>The transition from normal function to moderate airflow obstruction is generally gradual. Physiologists have searched for a test that is more sensitive than the FEV<sub>1</sub> for detection of airflow obstruction in its early stages. None has proven to be as reliable as the index obtained by dividing the FEV<sub>1</sub> by the FVC. The forced expiratory flow between 25 and 75 percent of the FVC (also known as FEF25-75 or maximal mid-expiratory flow rate) should not be used to detect "small airways disease" in adults, due to poor specificity and reproducibility [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Choosing the best values</span><span class="headingEndMark"> — </span>Report the highest FVC and the highest FEV<sub>1</sub> from three spirometric maneuvers, even if they are derived from different maneuvers [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Flow-volume loops</span><span class="headingEndMark"> — </span>The flow-volume loop is a plot of inspiratory and expiratory flow (on the Y-axis) against volume (on the X-axis) during the performance of maximally forced inspiratory and expiratory maneuvers. Changes in the contour of the loop can detect upper airway obstruction. The analysis of flow-volume loops is discussed separately. (See  <a class="medical medical_review" href="/d/html/1465.html" rel="external">"Flow-volume loops"</a>.)</p><p class="headingAnchor" id="H3882814528"><span class="h2">Post-bronchodilator spirometry</span><span class="headingEndMark"> — </span>In patients who have evidence of airflow limitation on baseline spirometry, and no prior diagnosis of asthma or COPD, post-bronchodilator spirometry may be useful. If post-bronchodilator spirometry is normal, COPD is less likely. The assessment of bronchodilator responses in patients with asthma-like symptoms is described separately. Note, however, that a bronchodilator response alone does not distinguish asthma from COPD [<a href="#rid47">47</a>]. If the change in spirometry post-bronchodilator does not support a diagnosis of obstructive lung disease, referral for bronchial challenge testing (eg, with <a class="drug drug_general" data-topicid="9622" href="/d/drug information/9622.html" rel="external">methacholine</a> or exercise) may be helpful [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/569.html" rel="external">"Pulmonary function testing in asthma", section on 'Bronchodilator responses'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">LIMITATIONS</span><span class="headingEndMark"> — </span>Office spirometry has some important limitations, even when all of the above-described quality measures are employed. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal spirometry results have little if any value in prompting smokers to quit [<a href="#rid49">49-53</a>]. All patients who smoke should be advised to stop smoking and provided smoking cessation assistance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a patient with asthma, which is characterized by variability in clinical symptoms and airflow obstruction, normal airflow at the time of office visits does not exclude airflow obstruction at other times.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with early interstitial lung disease may have normal spirometry and need further testing of gas transfer with a diffusing capacity of the lungs for carbon monoxide (DLCO) and/or exercise oximetry to identify the cause of dyspnea [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Misclassification rates due to suboptimal spirometry performance or interpretation are relatively high in the office setting [<a href="#rid7">7,17,55</a>]. Among eight general practices, rates for successfully meeting American Thoracic Society (ATS) quality standards were below 80 percent [<a href="#rid7">7</a>]. In 16 primary care offices involving 17 different spirometers, only 60 percent of patients had spirometry that met acceptability criteria [<a href="#rid17">17</a>]. Therefore, continuous quality review and feedback to nurses and technologists performing office spirometry are necessary and results should be verified by repeat testing in a Pulmonary Function Test (PFT) laboratory when important clinical decisions will be made based on the results [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are multiple barriers to performing in-office spirometry. One comprehensive survey identified multiple barriers including lack of knowledge about how to interpret spirometry, lack of resources (equipment, personnel, skills, time), and lack of belief in importance of results [<a href="#rid58">58</a>]. Most of the barriers identified were also true for out-of-office (ie, hospital) spirometry, indicating that implementing spirometry in general faces many challenges.</p><p></p><p class="headingAnchor" id="H16"><span class="h1">RISKS</span><span class="headingEndMark"> — </span>Spirometry is a low-risk procedure and has few side effects [<a href="#rid12">12</a>]. During the test, some patients may experience dizziness. The forced expiratory maneuver causes an increase in the pressure in the chest, abdomen, head, and eyes. In general, patients who have recently (eg, less than six weeks) had abdominal, intracranial, or eye surgery or a pneumothorax should not perform spirometry, although data are limited.</p><p>Spirometry requires exertion and should be avoided in patients with unstable angina or a recent myocardial infarction.</p><p>Rarely, performance of a forced expiratory maneuver will precipitate acute bronchoconstriction. This seems more likely to occur when a patient's asthma or COPD is poorly controlled. Treatment includes administering inhaled <a class="drug drug_general" data-topicid="9396" href="/d/drug information/9396.html" rel="external">albuterol</a> and supplemental oxygen.</p><p class="headingAnchor" id="H17"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Office spirometry is also useful for monitoring control of asthma The National Asthma Education and Prevention Program advises the following frequencies for spirometry testing when caring for patients with asthma [<a href="#rid59">59</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>At the time of initial assessment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After treatment is initiated and symptoms and peak flow have stabilized</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During periods of progressive or prolonged loss of asthma control</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At least every one to two years</p><p></p><p>For patients with chronic obstructive pulmonary disease (COPD), repeat spirometry is advised whenever there is a substantial increase in symptoms or decrease in exercise tolerance [<a href="#rid4">4,60,61</a>].</p><p>Office spirometry is also useful for monitoring disease progression in patients with idiopathic pulmonary fibrosis [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H1722013375"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118218.html" rel="external">"Society guideline links: Pulmonary function testing"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Spirometry is used to detect and monitor obstructive airway disease in patients with respiratory symptoms and risk factors. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Office spirometers should accurately measure the forced expiratory volume in one second (FEV<sub>1</sub>) and either the forced vital capacity (FVC) or the forced expiratory volume in six seconds (FEV<sub>6</sub>). Calibration checks should be performed daily with a three-liter syringe. (See <a class="local">'Quality control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since poorly performed maneuvers often mimic disease patterns, the clinician and technician must learn to recognize the patterns of unacceptable efforts  (<a class="graphic graphic_figure graphicRef57832" href="/d/graphic/57832.html" rel="external">figure 2</a>). (See <a class="local">'Quality control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An acceptable maneuver requires a sharp rise in the flow volume curve to the peak flow and an expiratory duration that reaches a plateau in expired volume or a duration of 15 seconds; however, if FEV<sub>6</sub> is being measured instead of FVC, then only a duration of at least six seconds is required. At least three good quality maneuvers should be performed. (See <a class="local">'Quality control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Report the highest FVC and the highest FEV<sub>1</sub> from three spirometric maneuvers, even if they are derived from different maneuvers. The fifth percentile lower limit of normal (LLN) for FEV<sub>1</sub>/FVC is preferred over the fixed threshold of 0.7 because it reduces the misclassification rate for detecting airway obstruction. (See <a class="local">'Choosing the best values'</a> above and <a class="local">'Ratio of FEV1/FVC'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduction of the FEV<sub>1</sub>/FVC suggests airway obstruction  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 1</a>) (see <a class="local">'Interpretation'</a> above). If FEV<sub>1</sub>/FVC is low but FEV<sub>1</sub> is normal, this is still considered obstruction but may also represent dysanapsis, which can be a normal variant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A normal FEV<sub>1</sub>/FVC but reduced FVC suggests restriction, which must be confirmed by lung volume measurement. If restriction is not confirmed, this pattern has been termed "nonspecific". If lung volumes are not available, a low FEV<sub>1</sub> and normal FEV<sub>1</sub>/FVC has also been referred to as Preserved Ratio Impaired Spirometry, or PRISm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The FEV<sub>1</sub>/FEV<sub>6</sub> can be helpful instead of FEV<sub>1</sub>/FVC when the FVC maneuvers are routinely stopped after six seconds. (See <a class="local">'Ratio of FEV1/FVC'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The FEV<sub>1</sub> should be used for determination of the degree of impairment and for serial comparisons in obstructive and mixed obstructive-restrictive disorders. It may also be used in the absence of lung volumes for grading previously confirmed restriction. FEV<sub>1</sub>/FVC ratio is not useful for gauging severity of ventilatory impairment, since the FVC often decreases with increasing obstruction due to air trapping or premature termination of exhalation  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 1</a>). (See <a class="local">'Interpretation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Office spirometry results should be verified by formal testing in a pulmonary function test (PFT) laboratory when important clinical decisions will be made based on the results. (See <a class="local">'Interpretation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite the potential benefits, ongoing barriers to office spirometry implementation include primary care provider uncertainty regarding the benefits of testing, lack of resources, and lack of confidence in spirometric interpretation.</p><p></p><p class="headingAnchor" id="H21135412"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Enright, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Enright P, Quanjer P. Don't diagnose mild COPD without confirming airway obstruction after an inhaled bronchodilator. COPD 2007; 4:89.</a></li><li><a class="nounderline abstract_t">Han MK, Kim MG, Mardon R, et al. Spirometry utilization for COPD: how do we measure up? Chest 2007; 132:403.</a></li><li><a class="nounderline abstract_t">Lee TA, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest 2006; 129:1509.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force (USPSTF), Siu AL, Bibbins-Domingo K, et al. Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 315:1372.</a></li><li><a class="nounderline abstract_t">Ruppel GL, Carlin BW, Hart M, Doherty DE. Office Spirometry in Primary Care for the Diagnosis and Management of COPD: National Lung Health Education Program Update. Respir Care 2018; 63:242.</a></li><li><a class="nounderline abstract_t">Enright PL, Studnicka M, Zielinski J. Spirometry to detect and manage COPD and asthma in the primary care setting. Eur Respir Mon 2005; 31:1.</a></li><li><a class="nounderline abstract_t">Walters JA, Hansen EC, Johns DP, et al. A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD. Thorax 2008; 63:408.</a></li><li><a class="nounderline abstract_t">Lusuardi M, De Benedetto F, Paggiaro P, et al. A randomized controlled trial on office spirometry in asthma and COPD in standard general practice: data from spirometry in Asthma and COPD: a comparative evaluation Italian study. Chest 2006; 129:844.</a></li><li><a class="nounderline abstract_t">Levy ML, Quanjer PH, Booker R, et al. Diagnostic spirometry in primary care: Proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations: a General Practice Airways Group (GPIAG)1 document, in association with the Association for Respiratory Technology &amp; Physiology (ARTP)2 and Education for Health3 1 www.gpiag.org 2 www.artp.org 3 www.educationforhealth.org.uk. Prim Care Respir J 2009; 18:130.</a></li><li><a class="nounderline abstract_t">Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med 2019; 200:e70.</a></li><li class="breakAll">United Kingdom National Screening Committee guidelines on COPD screening: https://view-health-screening-recommendations.service.gov.uk/document/329/download (Accessed on February 24, 2023).</li><li><a class="nounderline abstract_t">Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 2000; 117:1146.</a></li><li><a class="nounderline abstract_t">Culver BH, Graham BL, Coates AL, et al. Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med 2017; 196:1463.</a></li><li><a class="nounderline abstract_t">Townsend MC, Hankinson JL, Lindesmith LA, et al. Is my lung function really that good? Flow-type spirometer problems that elevate test results. Chest 2004; 125:1902.</a></li><li><a class="nounderline abstract_t">Liistro G, Vanwelde C, Vincken W, et al. Technical and functional assessment of 10 office spirometers: A multicenter comparative study. Chest 2006; 130:657.</a></li><li><a class="nounderline abstract_t">Schermer TR, Verweij EH, Cretier R, et al. Accuracy and precision of desktop spirometers in general practices. Respiration 2012; 83:344.</a></li><li><a class="nounderline abstract_t">Hegewald MJ, Gallo HM, Wilson EL. Accuracy and Quality of Spirometry in Primary Care Offices. Ann Am Thorac Soc 2016; 13:2119.</a></li><li><a class="nounderline abstract_t">Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009; 179:509.</a></li><li><a class="nounderline abstract_t">Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319.</a></li><li class="breakAll">Enright PL. Office spirometry. In: Atlas of office procedures, 1999. Vol 2, p.299.</li><li><a class="nounderline abstract_t">Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948.</a></li><li><a class="nounderline abstract_t">Vandevoorde J, Verbanck S, Schuermans D, et al. Forced vital capacity and forced expiratory volume in six seconds as predictors of reduced total lung capacity. Eur Respir J 2008; 31:391.</a></li><li><a class="nounderline abstract_t">Iyer VN, Schroeder DR, Parker KO, et al. The nonspecific pulmonary function test: longitudinal follow-up and outcomes. Chest 2011; 139:878.</a></li><li><a class="nounderline abstract_t">Swanney MP, Jensen RL, Crichton DA, et al. FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med 2000; 162:917.</a></li><li><a class="nounderline abstract_t">Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022; 60.</a></li><li><a class="nounderline abstract_t">Quanjer PH, Pretto JJ, Brazzale DJ, Boros PW. Grading the severity of airways obstruction: new wine in new bottles. Eur Respir J 2014; 43:505.</a></li><li><a class="nounderline abstract_t">Miller MR, Quanjer PH, Swanney MP, et al. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest 2011; 139:52.</a></li><li><a class="nounderline abstract_t">Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40:1324.</a></li><li><a class="nounderline abstract_t">Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008; 177:253.</a></li><li><a class="nounderline abstract_t">Bowerman C, Bhakta NR, Brazzale D, et al. A Race-neutral Approach to the Interpretation of Lung Function Measurements. Am J Respir Crit Care Med 2023; 207:768.</a></li><li><a class="nounderline abstract_t">Jakeways N, McKeever T, Lewis SA, et al. Relationship between FEV1 reduction and respiratory symptoms in the general population. Eur Respir J 2003; 21:658.</a></li><li><a class="nounderline abstract_t">Hnizdo E, Glindmeyer HW, Petsonk EL, et al. Case definitions for chronic obstructive pulmonary disease. COPD 2006; 3:95.</a></li><li><a class="nounderline abstract_t">Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax 2008; 63:1046.</a></li><li><a class="nounderline abstract_t">García-Rio F, Soriano JB, Miravitlles M, et al. Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. Chest 2011; 139:1072.</a></li><li><a class="nounderline abstract_t">Çolak Y, Afzal S, Nordestgaard BG, et al. Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. Eur Respir J 2018; 51.</a></li><li><a class="nounderline abstract_t">Smith BM, Kirby M, Hoffman EA, et al. Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. JAMA 2020; 323:2268.</a></li><li><a class="nounderline abstract_t">Vameghestahbanati M, Kirby M, Maltais F, et al. Dysanapsis and the Spirometric Response to Inhaled Bronchodilators. Am J Respir Crit Care Med 2021; 204:997.</a></li><li><a class="nounderline abstract_t">Forno E, Weiner DJ, Mullen J, et al. Obesity and Airway Dysanapsis in Children with and without Asthma. Am J Respir Crit Care Med 2017; 195:314.</a></li><li><a class="nounderline abstract_t">Wan ES, Balte P, Schwartz JE, et al. Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults. JAMA 2021; 326:2287.</a></li><li><a class="nounderline abstract_t">Marott JL, Ingebrigtsen TS, Çolak Y, et al. Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis. Am J Respir Crit Care Med 2021; 204:910.</a></li><li><a class="nounderline abstract_t">Zheng J, Zhou R, Zhang Y, et al. Preserved Ratio Impaired Spirometry in Relationship to Cardiovascular Outcomes: A Large Prospective Cohort Study. Chest 2023; 163:610.</a></li><li><a class="nounderline abstract_t">Jing JY, Huang TC, Cui W, et al. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis. Chest 2009; 135:991.</a></li><li><a class="nounderline abstract_t">Jensen RL, Crapo RO, Enright P. A statistical rationale for the use of forced expired volume in 6 s. Chest 2006; 130:1650.</a></li><li><a class="nounderline abstract_t">Bellia V, Sorino C, Catalano F, et al. Validation of FEV6 in the elderly: correlates of performance and repeatability. Thorax 2008; 63:60.</a></li><li><a class="nounderline abstract_t">Vollmer WM, Gíslason T, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J 2009; 34:588.</a></li><li><a class="nounderline abstract_t">Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179.</a></li><li><a class="nounderline abstract_t">Janson C, Malinovschi A, Amaral AFS, et al. Bronchodilator reversibility in asthma and COPD: findings from three large population studies. Eur Respir J 2019; 54.</a></li><li><a class="nounderline abstract_t">Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Buffels J, Degryse J, Decramer M, Heyrman J. Spirometry and smoking cessation advice in general practice: a randomised clinical trial. Respir Med 2006; 100:2012.</a></li><li><a class="nounderline abstract_t">Enright P. Does screening for COPD by primary care physicians have the potential to cause more harm than good? Chest 2006; 129:833.</a></li><li><a class="nounderline abstract_t">Bize R, Burnand B, Mueller Y, et al. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2012; 12:CD004705.</a></li><li><a class="nounderline abstract_t">Wilt TJ, Niewoehner D, Kane RL, et al. Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res 2007; 9:21.</a></li><li><a class="nounderline abstract_t">Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008; 336:598.</a></li><li><a class="nounderline abstract_t">Boros PW, Enright PL, Quanjer PH, et al. Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis. Eur Respir J 2010; 36:1315.</a></li><li><a class="nounderline abstract_t">Joo MJ, Au DH, Fitzgibbon ML, et al. Determinants of spirometry use and accuracy of COPD diagnosis in primary care. J Gen Intern Med 2011; 26:1272.</a></li><li><a class="nounderline abstract_t">Poels PJ, Schermer TR, Akkermans RP, et al. General practitioners' needs for ongoing support for the interpretation of spirometry tests. Eur J Gen Pract 2007; 13:16.</a></li><li><a class="nounderline abstract_t">Schermer TR, Smeele IJ, Thoonen BP, et al. Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J 2008; 32:945.</a></li><li><a class="nounderline abstract_t">Yamada J, Lam Shin Cheung J, Gagne M, et al. Barriers and Enablers to Objective Testing for Asthma and COPD in Primary Care: A Systematic Review Using the Theoretical Domains Framework. Chest 2022; 161:888.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Full text available online: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on August 12, 2009).</li><li><a class="nounderline abstract_t">Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 147:633.</a></li><li class="breakAll">Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. www.goldcopd.org (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Nathan SD, Wanger J, Zibrak JD, et al. Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons. Expert Rev Respir Med 2021; 15:175.</a></li></ol></div><div id="topicVersionRevision">Topic 6968 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530501" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Don't diagnose mild COPD without confirming airway obstruction after an inhaled bronchodilator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17550936" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Spirometry utilization for COPD: how do we measure up?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16778268" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Spirometry use in clinical practice following diagnosis of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27046365" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29367384" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Office Spirometry in Primary Care for the Diagnosis and Management of COPD: National Lung Health Education Program Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Spirometry to detect and manage COPD and asthma in the primary care setting</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18024537" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16608929" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A randomized controlled trial on office spirometry in asthma and COPD in standard general practice: data from spirometry in Asthma and COPD: a comparative evaluation Italian study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19684995" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diagnostic spirometry in primary care: Proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations: a General Practice Airways Group (GPIAG)1 document, in association with the Association for Respiratory Technology&amp;Physiology (ARTP)2 and Education for Health3 1 www.gpiag.org 2 www.artp.org 3 www.educationforhealth.org.uk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613151" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613151" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767253" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29192835" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15136405" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Is my lung function really that good? Flow-type spirometer problems that elevate test results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16963659" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Technical and functional assessment of 10 office spirometers: A multicenter comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22236628" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Accuracy and precision of desktop spirometers in general practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27598295" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Accuracy and Quality of Spirometry in Primary Care Offices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19136371" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lung function impairment and metabolic syndrome: the critical role of abdominal obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16055882" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Standardisation of spirometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16055882" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Standardisation of spirometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16264058" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Interpretative strategies for lung function tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17928313" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Forced vital capacity and forced expiratory volume in six seconds as predictors of reduced total lung capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20724741" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The nonspecific pulmonary function test: longitudinal follow-up and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10988105" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34949706" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : ERS/ATS technical standard on interpretive strategies for routine lung function tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23988764" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Grading the severity of airways obstruction: new wine in new bottles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20522571" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22743675" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18006882" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Reference ranges for spirometry across all ages: a new approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36383197" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A Race-neutral Approach to the Interpretation of Lung Function Measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12762353" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Relationship between FEV1 reduction and respiratory symptoms in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17175672" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Case definitions for chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18786983" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21183609" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29449425" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32515814" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34265233" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dysanapsis and the Spirometric Response to Inhaled Bronchodilators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27552676" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Obesity and Airway Dysanapsis in Children with and without Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34905031" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34233141" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Trajectory of Preserved Ratio Impaired Spirometry: Natural History and Long-Term Prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36372304" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Preserved Ratio Impaired Spirometry in Relationship to Cardiovascular Outcomes: A Large Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19349398" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166978" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A statistical rationale for the use of forced expired volume in 6 s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17702791" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Validation of FEV6 in the elderly: correlates of performance and repeatability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19460786" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9872837" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Spirometric reference values from a sample of the general U.S. population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31221806" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bronchodilator reversibility in asthma and COPD: findings from three large population studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461290" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16580189" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Spirometry and smoking cessation advice in general practice: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16608923" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Does screening for COPD by primary care physicians have the potential to cause more harm than good?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235615" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Biomedical risk assessment as an aid for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17365733" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18326503" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378598" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713542" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Determinants of spirometry use and accuracy of COPD diagnosis in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17366289" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : General practitioners' needs for ongoing support for the interpretation of spirometry tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18550607" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740591" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Barriers and Enablers to Objective Testing for Asthma and COPD in Primary Care: A Systematic Review Using the Theoretical Domains Framework.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740591" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Barriers and Enablers to Objective Testing for Asthma and COPD in Primary Care: A Systematic Review Using the Theoretical Domains Framework.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17975186" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17975186" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32985286" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
